

## **Data Sheet**

## WWW. UREIKO-CHEM. COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

 $\begin{tabular}{lll} \textbf{Product Name} & : Pirtobrutinib \\ \textbf{Cat.No.} & : URK-V963 \\ \textbf{CAS No.} & : 2101700-15-4 \\ \textbf{Molecular Formula} & : C_{22}H_{21}F_4N_5O_3 \\ \textbf{Molecular Weight} & : 479.436 \\ \textbf{Target} & : BTK \\ \textbf{Solubility} & : \\ \end{tabular}$ 

## **Biological Activity**

Pirtobrutinib (LOXO-305, LY3527727, RXC-005) is a highly potent and selective non-covalent BTK inhibitor with IC50 of 5.69 nM.

LOXO-305 shows nanomolar potency against both wild-type and C481-mutated BTK.

LOXO-305 displays >300 fold selectivity on BTK over 98% of other kinases, reducing the potential for off-target toxicities.

Pirtobrutinib (LOXO-305) has been designed to maintain greater than 90% of maximal BTK inhibition at trough, thereby achieving effective target inhibition throughout the dosing interval, even in proliferative tumours.

## References

- 1. Brandhuber B, et al. Clin. Lymphoma Myeloma Leuk. 2018;18:S216.
- 2. Ito K, et al. Eur J Cancer. 2021 Mar;145:183-193.

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!